Oral contraceptives' effects on the vascular component. Thrombophilic parameters

Annals of the New York Academy of Sciences

Volumn 900, Issue , 2000, Pages 228-236

  Kontopoulou, Irene ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

CONFERENCE PAPER; DEEP VEIN THROMBOSIS; FEMALE; HEMOSTASIS; HUMAN; ORAL CONTRACEPTION; RISK ASSESSMENT; THROMBOPHILIA;

EID: 0034094079     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06234.x     Document Type: Conference Paper

References (43)

1. 1. JORDAN, W.M. 1961. Pulmonary embolism. Lancet ii: 1146-1147.
2. 2. VESSEY, M.P. & R. DOLL. 1969. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. Br. M.J. ii: 651-657.
3. 3. SARTWELL, P.E., A.T. MASI, F.D.G. ARTHES et al. 1969. Thromboembolism and oral contraceptives: an epidemiologic case control study. Am. J. Epidemiol. 90: 365-380.
4. 4. VESSEY, M.P., R. DOLL, A.E. Fairburn & G. GLOBER. 1970. Prospective thromboembolism and use of oral contraceptives. Br. Med. J. iii: 123-126.
5. 5. MAQUIRE, M., J. TONOSIA, P.E. SARTWELL et al. 1979. Increased risk of thrombosis due to oral contraceptives: a further report. Am. J. Epidemiol. 110: 188-195
6. 6. VESSEY, M.P., D. MANT, A. SMITH & D. YEATES. 1986. Oral contraceptive and venous thromboembolism: findings in a large prospective study. Br. Med. J. 292: 526.
7. 7. HELMRICH, S.P., L. ROSEMBERG, D.W. KAUFMAN et al. 1987. Venous thromboembolism in relation to oral contraceptive use. Obstet. Gynecol. 69: 91-95.
8. 8. STALLEY, P.D., J.A. TONASCIA, M.S. TOCKMAN et al. 1975. Thrombosis with low estrogen oral contraceptives Am. J. Epidemiol. 102: 197.
9. 9. INMAN, W.H.W., M.P. VESSEY, B. WESTERHOLM & A. ENGELNUD. 1970. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br. Med. J. ii: 203-209.
10. 10. GESTMANN, B.B., J.M. PIPER, J.P. FREIMAN et al. 1990. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Am. J. Epidemiol. 4: 931-936.
11. 11. JICK, H., S. JICK, V. GUREWICK, M. MAYERS & C. VASILAKIS. 1995. Risk of idiopathic caridiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589-1593.
12. 12. SPITZER, W., M. LEWIS, L. HEINEMANN et al. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. 1996. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med. J. 312: 83-88.
13. 13. WORLD HEALTH ORGANIZATION. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. 1995. Venous thromboembolic disease and combined oral contraceptives: result of international multicentre case-control study. Lancet 346: 1575-1581.
14. 14. WORLD HEALTH ORGANIZATION. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. 1995. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582-1588.
15. 15. POLLER, L. 1978. Oral contraceptives, blood clotting and thrombosis. Br. Med. Bull. 34: 151-156.
16. 16. BONNAR, J. 1987. Coagulation effects of oral contraception. Am. J. Obstet. Gynecol. 157: 1042-1048.
17. 17. BRUNI, V., R. ABBATE, S. PINTO et al. 1987. Effects of gestodene on haemostasis. Gynecological Endocrinology. : 523-532. Parthenon Publishing. Carnforth, U.K.
18. 18. COHEN, H., I.J. MACKIE, K. WALSHE et al. 1988. A comparison of the effects of two thriphasic oral contraceptives on haemostasis. Br. J. Haematol. 69: 259-263.
19. 19. ABBATE, R., S. PINTO, C. ROSTAGNO et al. 1990. Effects of long-term gestodene-containing oral contraceptive administration on haemostasis. Am. J. Obstet. Gynecol. 163: 424-430.
20. 20. FOTHERBY, K. 1994. Are changes in haemotological factors and cardiovascular risk during oral contraceptives use dose related? Fertil. Control Rev. 3: 11-15.
21. 21. CREATSAS, G., I. KONTOPOULOU-GRIVA, E. DELIGEORGIOU et al. 1997. Effects of two combined monophasic and thriphasic ethinylestradiol gestrodene oral contraceptives on natural inhibitors and other hemostatic variables. Eur. J. Contracept. Reprod. Health Care 2: 1-8.
22. 22. DAHLBACK, B., M. CARLSSON & P.J. SVENSSON. 1993. Familiar thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90: 1004-1008.
23. 23. BERTINA, R.M., B.P.C. KOELEMAN, T. KOSTER et al. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67.
24. 24. REES, D.C., M. Cox & J.B. CLEGG. 1995. World distribution of factor V Leiden. Lancet 346: 1133-1134.
25. 25. POORT, R.S., F.R. ROSENDAAL, P.H. REITSMA & R.M. BERTINA. 1996. A common genetic varation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88: 3699.
26. 26. ROSENDAAL, F.R., C.J.M. DOGGEN, A. ZIVELIN et al. 1998. Geographic distibution of the 20210 G to A prothrombin variant. Thromb. Haemostasis 79: 706-708.
27. 27. MALM, J., M. LAURELL & B. DAHLBACK. 1998. Changes in the plasma levels of vitamin K-dependent protein C and S and of C4b-binding protein during pregnancy and oral contraception. Br. J. Haematol. 68: 437-443.
28. 28. BLOEMENKAMP, K., F. ROSENDAAL, F. HELMERSHOST et al. 1998. Hemostastic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb. Haemostasis 80: 382-387.
29. 29. PABINGER, I. & B. SCHNEIDER and the GTH Study Group on Natural Inhibitors. 1994. Thrombotic risk of women with hereditary antithrombin III. -protein C- and protein S-deficiency taking oral contraceptive medication. Thromb. Haemostasis 71: 548-552.
30. 30. SVENSSON, P.J. & B. DAHLBACK. 1994. Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330: 517-522.
31. 31. HENKENS, C., V. BOM, A. SEINEN & J. VAN DER MEER. 1995. Sensitivity to activated protein C. Influence on oral contraceptives and sex. Thromb. Haemostasis 73: 402-404.
32. 32. OLIVIERI, O., S. FRISO, F. MANZATO & A. GUELLA. 1995. Resistance to activated protein C in healthy women taking oral contraceptives. Br. J. Haematol. 91: 465-470.
33. 33. CUMMING, A.M., R.C. TAIT, S. FILDES et al. 1995. Development of resistance to activated protein C during pregnancy. Br. J. Haematol. 90: 725-727.
34. 34. ROSING, J., G. TANS, G. NICOLAES et al. 1997. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br. J. Haematol. 97: 233-238.
35. 35. VANDENBROUCKE, J. & F. ROSENDAAL. 1997. End of the line for "third-generation-pill" controversy? Lancet 349: 1113-1114.
36. 36. HELMERHOST, F.M., K.W.M. BLOEMENKAMP, E. BRIET et al. 1996. Factor V Leiden mutation and contraception. Gynecol. Endocrinol. 10: 85-87.
37. 37. SOUTO, J.C., I. COLL, D. LIOBE et al. 1998. The prothrombin 20210 A allele is the most prevalent genetic risk factor for venous thromboembolism in Spanish population. Thromb. Haemostasis 80: 366-369.
38. 38. MARTINELLI, I., G. LANDI, G. MERATI et al. 1996. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb. Haemostasis 75: 393-394.
39. 39. MARTINELLI, I., F.R. ROSENDAAL, J.P. VANDENBROUCKE & P.M. MANNUCCI. 1996. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb. Haemostasis 76: 477-478.
40. 40. DE BRUIJN, S.F.T.M., J. STAM, M.M.W. KOOPMAN & J.P. VANDENBROUCKE for the Cerebral Venous Sinus Thrombosis Study Group. 1998. Case control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Br. Med. J. 316: 589-592.
41. 41. MARTINELLI, I., E. SACCHI, G. LANDI et al. 1998. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N. Engl. J. Med. 338: 1793-1797.
42. 42. VANDERBROUCKE, J.P., F.J.M. VAN DEN MEER, F.M. HELMERHORST & F.R. ROSENDAAL. 1996. Factor V Leiden: should we screen oral contraceptive users and pregnant women? Br. J. Med. 313: 1127-1130.
43. 43. ROSENDAAL, F.R. 1995. Oral contraceptives and screening for factor V Leiden. Thromb. Haemostasis 75: 524-533.